Burning Rock Biotech rises on 'breakthrough' tag for cancer detecting blood test

Burning Rock Biotech

03/01/2023 15:17

** Cancer therapy developer Burning Rock Biotech  BNR.O  up
20% at $2.7 in opening trade of 2023
    ** U.S. FDA grants Breakthrough device tag to co's blood
test kit for early detection of multiple types of cancer in
adults aged between 50-75 years
    ** The breakthrough tag is a formal identification by the
FDA that a device in development should be expedited for patient
access by speeding up their development, assessment, and review
processes
    ** The kit demonstrated a 69.1% of sensitivity and 98.9% of
specificity in a study - BNR
    ** Stock had declined 76.4% in 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))